Heidi C. Fantasia, PhD, RN, WHNP-BC
University of Massachusetts Lowell
Solomont School of Nursing
Allyssa L. Harris, RN, PhD, WHNP-BC
WHNP Program Director
William F. Connell School of Nursing
Chestnut Hill, Massachusetts
Nurse practitioners (NPs), Certified Nurse-Midwives (CNMs), and other advanced practice clinicians who care for women.
- CE Approval Period: Now through December 2019
- Estimated Time to Complete This Activity: 1.5 hours
- CE Approval Hours: 1.5 Contact Hours of CE Credit including 0.5 contact hours of pharmacology credit
At the conclusion of this activity, clinicians should be better able to:
- Identify risk factors for & symptoms suggestive of UF to improve diagnosis & treatment as part of comprehensive women's healthcare.
- Compare available options for managing UF to facilitate the appropriate use of minimally-invasive treatments.
- Implement strategies that assess individual patient goals and preferences considering all UF treatment options, to inform decision-making.
- Assess the potential clinical implications of novel pharmacotherapies as part of the comprehensive management of UFs.
Successful Completion of the Activity:
Successful completion of this online activity, 18-04-09, requires the participant to:
During the approval period (now through December 2019);
- Read the educational objectives, disclosures, and disclaimers in the Front Matter section;
- Study the material in the learning activity by watching the session;
- Complete the post test with a score of 70% or higher;
- Complete the session evaluation;
- After successful completion you may print your CE certificate. Your certificate will be stored for you on the NPWH E-Learning site under My Transcripts
Uterine fibroids (UF) affect up to 80% of women by age 50 and as many as 25% of women of reproductive age. UFs often cause heavy menstrual bleeding, pain, depression, and can negatively impact fertility and pregnancy outcomes. Despite the availability of a number of minimally invasive procedures to remove UF, as well as the potential availability of novel pharmacotherapy options, these treatments are infrequently discussed with patients. As such, hysterectomy remains the most common treatment, despite representing the least preferred procedure. This activity is designed to provide NPs with education focusing on the identification of women at risk for or experiencing UF and the efficacy and safety of minimally invasive surgical strategies and novel, investigational medical management strategies. This activity will also emphasize the importance of considering and communicating all available UF management options to individualize treatments.
This activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health (NPWH), and has been approved for 1.5 contact hour(s) of CE credit including 0.5 contact hours of pharmacology credit. Each participant should claim only those contact hours that he/she actually spent in the educational activity.
Activity Number: 18-04-09
NPWH policy requires all faculty to disclose any affiliation or relationship with a commercial interest that may cause a potential, real, or apparent conflict of interest with the content of a CE program. NPWH does not imply that the affiliation or relationship will affect the content of the CE program. Disclosure provides participants with information that may be important to their evaluation of an activity. All conflicts of interest were resolved according to NPWH policy. In addition, all content has been peer reviewed by a WHNP with no conflicts of interest to ensure the content is evidence-based, un-biased, and uses the best available, highest strength evidence for recommendations. Faculty are also asked to identify any unlabeled/unapproved uses of drugs or devices made in their presentation.
Heidi C. Fantasia, PhD, RN, WHNP-BC has nothing to disclose.
Allyssa L. Harris, RN, PhD, WHNP-BC has nothing to disclose.
Disclosure of unlabeled use:
NPWH policy requires authors to disclose to participants when presenting information about unlabeled use of a commercial product or device or an investigational use of a drug or device not yet approved for any use.
Participating faculty members determine the editorial content of CE activities; this content does not necessarily represent the views of NPWH. This content has undergone a blinded peer review process for validation of clinical content. Although every effort has been made to ensure that the information is accurate, clinicians are responsible for evaluating this information in relation to generally accepted standards in their own communities and integrating the information in this activity with that of established recommendations of other authorities, national guidelines, FDA approved package inserts, and individual patient characteristics.
This activity was supported by an educational grant from Allergan.
You must be signed in to access this course. You can sign in at the top right-hand corner of the page.
**If you are an NPWH member, were once a member, or have taken CE activities with NPWH in the past, you have a username and password in our new system. Please DO NOT create a new account. Creation of multiple accounts could result in loss of CE credits as well as other NPWH services. If you do not remember your username or password, please either click on the "forgot username" or "forgot password" links at the bottom of the sign in screen or call the NPWH office at (202) 543-9693 ext. 1.**